Over $22.8 billion from M&A deals in the first half of the year was returned to specialist biotech investors. This capital is being rapidly redeployed back into the sector, creating a significant tailwind that can explain otherwise news-free stock jumps in various biotech companies.
While biotech is funded by specialist firms, many of those firms' Limited Partners (LPs) are generalists with large AI holdings. An AI market crash could cause losses for these LPs, forcing them to make capital calls and withdraw money from specialist biotech funds, creating an unexpected liquidity crunch.
Despite positive sales figures, several biotech companies with recent product launches have seen flat or declining stock performance. This suggests investors either have overinflated expectations that even good numbers cannot meet, or they are simply not yet convinced by the long-term commercial stories.
In multiple instances where siRNA and ASO (antisense) therapies have been developed for the same indication, the siRNA drug has emerged with a superior overall profile across efficacy, safety, and dosing convenience. This pattern suggests siRNA is solidifying its position as the more advantageous modality.
Takeda's leadership in the competitive orexin space for narcolepsy resulted from a key R&D strategy: they had already begun developing an improved backup compound before their initial Phase 2 candidate showed a toxicity signal. This foresight allowed an immediate pivot, preserving momentum and gaining a competitive edge.
A Takeda executive compared the potential of its orexin program to the "GLP-1 moment for neuroscience." This framing suggests the drug's mechanism could have broad utility beyond narcolepsy, potentially becoming a foundational platform for numerous neurological disorders, much like GLP-1s transformed metabolic disease.